Health care provider REMS-certified status
Read this section in the full bill →
This section appears in one version only, so there is nothing to compare yet.
(a) In-Person visit required Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug without an in-person visit with the patient for whom such drug is prescribed shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years. (b) License in patient’s State required Any REMS-certified provider that knowingly prescribes, dispenses, or administers mifepristone or any other abortion drug to a patient residing in a State where the provider does not have a medical license shall lose REMS-certified status, with respect to such drug, for a period of not less than 2 years. (c) Reporting The Secretary shall, on an annual basis, submit to Congress a report listing each REMS-certified provider who has lost REMS-certified status due to— (1) a violation of this section; or (2) improper or unsafe prescribing of mifepristone or any other abortion drug. (d) Definitions In this section: (1) Abortion drug The term abortion drug means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than— (A) to produce a live birth; (B) to remove a dead unborn child; or (C) to treat an ectopic pregnancy. (2) REMS-certified status The term REMS-certified status means, with respect to mifepristone or any other abortion drug, the certification of a REMS-certified provider by the Secretary to dispense such drug pursuant to a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1). (3) REMS-certified provider The term REMS-certified provider means a health care professional who has successfully completed the FDA’s Risk Evaluation and Mitigation Strategy (REMS) certification program for prescribing mifepristone. (4) Secretary The term Secretary means the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs.